W.L.Gore & Associates

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, W.L.Gore & Associates sits in the top decile of US sponsors by registered trial count (#359 of 15,742 sponsors by registered trial count).

53 total trials 11 currently recruiting 25 completed later-stage tilt top decile by trial count

W.L.Gore & Associates: 53 sponsored US clinical trials, 11 recruiting.

W.L.Gore & Associates sponsors 53 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 25 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Aortic Aneurysm, Thoracic, with 3 trials.

Top-decile sponsor footprint

W.L.Gore & Associates ranks in the top decile of sponsors by registered trial count (#359 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 35/100

25 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

53 total, page 1 of 2

RECRUITING NA

GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study

NCT07166133
RECRUITING NA

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

NCT06827990
RECRUITING

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

NCT06658730
RECRUITING

Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease

NCT06872905
RECRUITING NA

Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)

NCT06556654
RECRUITING

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875
RECRUITING NA

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

NCT05811364
RECRUITING NA

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588
RECRUITING NA

GORE® ENFORM Biomaterial Product Study

NCT04718168
RECRUITING NA

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT04671771
RECRUITING NA

GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

NCT03821129
ACTIVE NOT RECRUITING NA

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study

NCT06578741
ACTIVE NOT RECRUITING

Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application

NCT05094089
ACTIVE NOT RECRUITING NA

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

NCT05409976
ACTIVE NOT RECRUITING NA

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

NCT03728985
ACTIVE NOT RECRUITING NA

Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction

NCT03441971
ACTIVE NOT RECRUITING NA

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

NCT02489539
ACTIVE NOT RECRUITING NA

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

NCT02777593
ACTIVE NOT RECRUITING NA

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1

NCT02777528
ACTIVE NOT RECRUITING

ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection

NCT02380716
ACTIVE NOT RECRUITING

Global Registry for Endovascular Aortic Treatment (GREAT)

NCT01658787
TERMINATED NA

GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

NCT04100135
TERMINATED NA

Evaluating the Safety and Effectiveness of the InnAVasc Graft for Dialysis Access in Patients With Kidney Failure

NCT03645681
COMPLETED NA

Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs

NCT02985684
COMPLETED NA

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms

NCT02528500
COMPLETED NA

In-Stent Restenosis Post-Approval Study

NCT02542267
COMPLETED NA

Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms

NCT02264977
COMPLETED NA

A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.

NCT02080871
TERMINATED NA

Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients

NCT02165761
COMPLETED NA

Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms

NCT02021812
COMPLETED NA

Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis

NCT01883999
COMPLETED NA

The Gore SCAFFOLD Clinical Study

NCT01901874
TERMINATED

Evaluation of GORE® VIABAHN® Endoprosthesis for Popliteal Artery Aneurysm

NCT01902888
COMPLETED NA

Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects

NCT01711983
COMPLETED NA

Evaluation of the GORE TIGRIS Vascular Stent

NCT01576055
COMPLETED NA

GORE Flow Reversal System and GORE Embolic Filter Extension Study

NCT01343667
COMPLETED

Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement

NCT01325792
TERMINATED NA

Early TIPS for Ascites Study

NCT01236339
COMPLETED NA

Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection

NCT00917852
COMPLETED NA

Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection

NCT00908388
COMPLETED NA

Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic

NCT00874250
COMPLETED NA

GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients

NCT00738894
COMPLETED Phase 3

GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis

NCT00737672
TERMINATED NA

Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses

NCT00663819
TERMINATED Phase 4

GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft

NCT00617279
COMPLETED NA

GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)

NCT00541307
COMPLETED Phase 2

GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta

NCT00608829
COMPLETED NA

Long-term Safety Study of the GORE® HELEX® Septal Occluder

NCT00581308
COMPLETED Phase 3

GORE Embolic Protection With Reverse Flow

NCT00594100
COMPLETED Phase 2

Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms

NCT00615069
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 2
Phase 4 2

Therapeutic Areas

Aortic Aneurysm, Thoracic 3
Aorta; Lesion 2
Carotid Artery Stenosis 2
Vein Disease 2
Vein Occlusion 2
Vein Thrombosis 2
Venous Disease 2
Venous Thromboses 2
Aortoiliac Occlusive Disease 2
Venous Occlusion 2

Where W.L.Gore & Associates enrollment is open (later-stage tilt)

11 recruiting of 53 indexed (21% open); 25 completed (47%).

Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Aortic Aneurysm, Thoracic (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

W.L.Gore & Associates: open-pipeline peers nationwide

Peers matched on 53 registered trials and 21% open enrollment, not the therapeutic-area sidebar.

W.L.Gore & Associates sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%10%20%30%40% Total trials Recruiting share W.L.Gore & AssociatesBioNTech SESociété des Produits Nestlé (SPN)Warner ChilcottAdventHealth Translational Research InstituteCraig HospitalGeorgia Institute of TechnologyUniversity of Colorado, DenverCedars-Sinai Medical Center
W.L.Gore & Associates sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

W.L.Gore & Associates sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 53 trials (± recruiting share)

Sponsors near 21% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this W.L.Gore & Associates page

53 registered trials is a research-attention snapshot, not an endorsement of W.L.Gore & Associates or any single study.

  • 11 of W.L.Gore & Associates's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Aortic Aneurysm, Thoracic is the condition W.L.Gore & Associates studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Aortic Aneurysm, Thoracic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

W.L.Gore & Associates pipeline card: 53 registered trials from official public datasets.Report a data error.